Effects of treatment changes on asthma phenotype prevalence and airway neutrophil function

BMC Pulmonary Medicine 
Collin R. Brooks, Christine J. Van DalenElizabeth HardingIan F. Hermans and Jeroen Douwes

Abstract

Background

Asthma inflammatory phenotypes are often defined by relative cell counts of airway eosinophils/neutrophils. However, the importance of neutrophilia remains unclear, as does the effect of ICS treatment on asthma phenotypes and airway neutrophil function. The purpose of this study was to assess asthma phenotype prevalence/characteristics in a community setting, and, in a nested preliminary study, determine how treatment changes affect phenotype stability and inflammation, with particular focus on airway neutrophils.

Methods

Fifty adult asthmatics and 39 non-asthmatics were assessed using questionnaires, skin prick tests, spirometry, exhaled nitric oxide (FENO) measurement, and sputum induction. Twenty-one asthmatics underwent further assessment following treatment optimisation (n = 11) or sub-optimisation (n = 10).

Results

Forty percent (20/50) had eosinophilic asthma (EA) and 8% had neutrophilic asthma. EA was associated with increased FENO, bronchodilator reversibility (BDR) and reduced lung function (p < 0.05). Following optimisation/sub-optimisation, the EA/NEA (non-eosinophilic asthma) phenotype changed in 11/21 (52%) asthmatics. In particular, fewer subjects had EA post treatment optimisation, but this was not statistically significant. However, a significant (p < 0.05) reduction in FENO, ACQ7 score, and BDR was observed after treatment optimisation, as well as an increase in FEV1-% predicted (p < 0.05). It was also associated with reduced eosinophils (p < 0.05) and enhanced neutrophil phagocytosis (p < 0.05) in EA only, and enhanced neutrophil oxidative burst in both EA and NEA (p < 0.05).

Conclusions

In this community based population, non-eosinophilic asthma was common, less severe than EA, and at baseline most asthmatics showed no evidence of inflammation. In the nested change in treatment study, treatment optimisation was associated with reduced sputum eosinophils, improved symptoms and lung function, and enhanced neutrophil function, but a significant reduction in EA could not be demonstrated.

Trial registration

The nested change in treatment component of this study is registered at the Australia and New Zealand Clinical Trial Registry (www.ANZCTR.org.auACTRN12617001356358. Registration date 27/09/2017. Retrospectively registered.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Autism risk determined by health of mom's gut, research reveals https://t.co/nt9cDWUj7t, see more https://t.co/CpGiFuOOYd
1hreplyretweetfavorite
Interasma RT @ARIAGuideline: Electronic Clinical Decision Support System for AR management: The Allergy Diary Companion app for health care providers…
9hreplyretweetfavorite
Interasma RT @Aller_MD: Antibody Responses Against S. Aureus in Atopic Dermatitis. Might an altered immune response towards various S. aureus antigen…
9hreplyretweetfavorite
Interasma RT @Aller_MD: Olfactory receptors 'do more than smell'. Human olfactory receptors are everywhere in the body — not just in the nose — and m…
9hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergists on Social Media! https://t.co/Q0v2skrerV Thanks to @ERSpublications @COPDdoc @EMJRespiratory #mhr #tb
9hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma